Product Description
IL-2 fused to anti-PD-1 being developed by GENUV for solid tumors. (Sourced from: https://genuv.com/pipeline/pipeline-en)
Mechanisms of Action: IL2 Inhibitor,PD-1 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GENUV
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/15/2023 |
News Article |
Genuv Teams With Celltrion to Develop Novel mAb Treatments / Genuv Embarks on Mouse Platform Business |
|
03/15/2023 |
News Article |
Genuv Teams With Celltrion to Develop Novel mAb Treatments / Genuv Embarks on Mouse Platform Business |
|
10/13/2022 |
News Article |
Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Regresses Tumor Growth Without Toxicity |
|
08/18/2022 |
News Article |
Publication in Nature Molecular Psychiatry Supports Genuv's Alternate Theory for Treatment of Alzheimer's Disease |